Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats

Anesthesia and Analgesia

Volumn 86, Issue 1, 1998, Pages 74-81

  Horstman, Damian J ^a   Frank, Deborah U ^a   Rich, George F ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCROTALINE; NITRIC OXIDE; OXYGEN; VASODILATOR AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; CONTROLLED STUDY; HEART RIGHT VENTRICLE HYPERTROPHY; HYPOXIA; INHALATIONAL DRUG ADMINISTRATION; LUNG BLOOD VESSEL; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; THICKNESS;

ADMINISTRATION, INHALATION; ANIMALS; ANOXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; NITRIC OXIDE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031964318     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199801000-00015     Document Type: Article

References (27)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
2. Roos CM, Frank DU, Xue C, et al. Chronic inhaled nitric oxide: effects on pulmonary vascular endothelial function and pathology in rats. J Appl Physiol 1996;80:252-60.
3. Rich GF, Roos CM, Anderson SM, et al. Inhaled nitric oxide: dose response and the effects of blood in the isolated rat lung. J Appl Physiol 1993;75:1278-84.
4. Rossaint R, Falke K, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328: 399-405.
5. Lowson SM, Rich GF, McArdle PA, et al. The response to varying concentrations of inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesth Analg 1996;82: 574-81.
6. Roberts JD, Fineman JR, Morin FC, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997;336:605-10.
7. Maruyama, J, Maruyama K, Mitani Y, et al. Continuous low-dose NO inhalation does not prevent monocrotaline-induced pulmonary hypertension in rats. Am J Physiol 1997;272: H517-24.
8. Meyrick B, Gamble W, Reid L. Development of crotalaria pulmonary hypertension: hemodynamic and structural study. Am Physiol 1980;239:H692-702.
9. Kouyoumdjian C, Adnot S, Levame M, et al. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J Clin Invest 1994;94:578-84.
10. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrate: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci 1990;87:1620-4.
11. Stephens RJ, Freeman G, Evans MJ. Early response of lungs to low levels of nitrogen dioxide. Arch Environ Health 1972;24: 160-79.
12. Puybasset L, Rouby JJ, Mourgeon E, et al. Inhaled nitric oxide in acute respiratory failure: dose-response curves. Intensive Care Med 1994;20:319-27.
13. Stewart TE, Valenza F, Ribeiro SP, et al. Increased nitric oxide in exhaled gas as an early marker of lung inflammation in a model of sepsis. Am J Respir Crit Care Med 1995;151:713-8.
14. Frostell CG, Blomqvist H, Hedenstierna G, et al. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesth 1993;78: 427-35.
15. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
16. Roberts JD, Roberts CT, Jones RC, et al. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat. Circ Res 1995;76:215-22.
17. Stanbrook HS, Morris KG, McMurtry IF. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists. Am Rev Respir Dis 1984;130:81-5.
18. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31.
19. Hassoun PM, Thompson BT, Hales CA. Partial reversal of hypoxic pulmonary hypertension by heparin. Am Rev Respir Dis 1992;145:193-6.
20. Ono S, Westcott JY, Voelkel NF. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. J Appl Physiol 1992;73:1084-92.
21. Lipke DW, Arcot SS, Gillespie MN, Olson JW. Temporal alterations in specific basement membrane components in lungs from monocrotaline-treated rats. Am J Respir Cell Mol Biol 1993;9:418-28.
22. Kitayama Y, Hatanaka K, Hayashi T, et al. Effects of inhaled nitric oxide in rats with chemically induced pulmonary hypertension. Respir Physiol 1994;97:301-7.
23. Chen EP, Bittner HB, David RD, Trigt PV. Right ventricular failure-insights provided by a new model of chronic pulmonary hypertension. Transplant 1997;63:209-16.
24. Takashi T, Kanda T, Inoue M, et al. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci 1996;59:371-7.
25. Takahashi T, Kanda T, Imai S, et al. Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Res Commun Mol Pathol Pharmacol 1996;91:17-32.
26. Rabinovitch M, Gamble W, Nadas AS, et al. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am T Physiol 1979;236:H818-27.
27. Nishimura M, Hess D, Kacmarek RM, et al. Nitrogen dioxide production during mechanical ventilation with nitric oxide in adults. Anesth 1995;82:1246-54.